A high expression of CD98hc has been related to the histopathological features and clinical prognosis in patients with many solid cancers, such as head and neck squamous cell carcinoma (HNSCC), glioma, colon adenocarcinoma, pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) and breast cancer (18, 35–41), and tumor response to conventional therapies, such as chemo- and radiotherapy (11, 42, 43). This evidence concerns the gene SLC3A2 and breast carcinoma.